BDSI BioDelivery Sciences International Inc.

BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference

BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference

RALEIGH, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeff Bailey, Chief Executive Officer, and Terry Coelho, Chief Financial Officer, will participate in a fireside chat and 1x1 investor meetings at the Piper Sandler 32nd Annual Healthcare Conference.

The pre-recorded fireside chat will be available for viewing beginning November 23rd through December 3rd by accessing the recording library on the Piper Sandler conference site. BDSI will be hosting 1x1 investor meetings on Wednesday, December 2nd and Thursday, December 3rd. Meetings may be requested exclusively via Piper Sandler.

ABOUT BIODELIVERY SCIENCES INTERNATIONAL, INC.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.

© 2020 BioDelivery Sciences International, Inc.  All rights reserved.

Contact:

Terry Coelho

Chief Financial Officer

 

Bob Yedid

LifeSci Advisors

(646) 597-6989

 



EN
20/11/2020

Underlying

Reports on BioDelivery Sciences International Inc.

 PRESS RELEASE

BioDelivery Sciences International Announces ELYXYB™ is Now Available ...

BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio and Establishes Growth Platform in Neurology RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availa...

 PRESS RELEASE

Collegium to Acquire BioDelivery Sciences in an All-Cash Deal

Collegium to Acquire BioDelivery Sciences in an All-Cash Deal Transaction is valued at $5.60 per share representing a total equity value of $604 million Represents a 54% premium to BDSI stock’s closing price of $3.64 on February 11, 2022 and a 65% premium to the 30 trading days volume weighted average price of $3.40 Transaction expected to close late in the first quarter of 2022 RALEIGH, N.C., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic...

 PRESS RELEASE

BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year...

BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance Total 2021 Net Revenue expected in the range of $165 -$167 million, as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 -$148 million, as compared to previous guidance of $144-$148 million 2021 EBITDA expected to be in the $40 - $45 million range as compared with previous guidance of

BIODELIVERY SCIENCES sees an upgrade to Slightly Positive due to a bet...

The general evaluation of BIODELIVERY SCIENCES (US), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date December 21, 2021, the closing pric...

 PRESS RELEASE

BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining ...

BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032 RALEIGH, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that the U.S. District Court of Delaware has issued an opinion in favor of BDSI in the company’s patent litigation against Alvogen Group, Inc. and its affiliates, who filed an Abbreviated New Drug Application (ANDA) for BDSI’s BELBUCA® prod...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch